On Thursday, August 7, Eli Lilly's stock (NYSE:LLY) dropped by 14%, even though the company announced a strong quarter with earnings, revenues, and guidance that exceeded market expectations. This ...

Microsoft posts strong cloud-fueled Q1 results as Azure surges and AI momentum builds, even as capacity limits pose near-term ...

Eli Lilly's (NYSE: LLY) market isn't out of the weeds yet but will rebound strongly in 2025. The Q3 results failed to spark a rally because of underperformance, but the salient details are that growth ...

Shares of Eli Lilly plummeted 14% on Thursday, pacing what would be the stock’s largest loss in decades after the pharmaceutical giant unveiled data for its obesity treatment pill that fell behind ...

In an Aug. 7 earnings call, Eli Lilly CEO David Ricks told investors that the company plans to submit the drug, orforglipron, to the FDA for approval by the end of the year. Dan Skovronsky, chief ...

Indianapolis-based Eli Lilly is the first publicly traded U.S. healthcare company to reach market capitalization over $1 trillion, elevating the drugmaker to an exclusive list dominated by tech giants ...

reported better-than-expected earnings for the fourth quarter. The Indianapolis, Indiana-based company posted quarterly earnings of $428.5 million, or $0.40 per share, compared to $727.5 million, or ...

The two drugmakers swiftly denied any affiliation with Mangoceuticals, who claimed it had partnered with them.